Federal Health Grants

This Notice of Funding Opportunity (NOFO) invites applications for a U54 Specialized Center (henceforth: Consortium) to provide resources, expertise, and coordination to advance innovative, high-quality research on palliative care for those with serious illness across the lifespan. This research infrastructure will encompass Alzheimers disease and Alzheimers disease-related dementias (AD/ADRD), cancer, and other serious illnesses and populations relevant to the partnering Institutes, Centers, and Offices (ICOs). NIH currently funds many palliative care research projects across the ICOs, and there is a need for a structure to leverage synergies, coordinate efforts, develop the scientific workforce, and address remaining gaps in the field. The goals of this initiative include generating new scientific knowledge, in part through supporting pilot and exploratory studies; fostering development of early- and mid-career palliative care investigators; serving as a national platform to provide research resources and facilitate high-quality palliative care research; engaging healthcare systems and community-based organizations as research partners and settings for palliative care research; and disseminating research findings, best practices, data, and other impactful resources to the palliative care research and clinical communities. An important focus of the Consortiums work will be on facilitating research to understand and address disparities in access, quality, and use of palliative care services for health disparities populations or in underserved areas.

This funding opportunity provides financial support to various organizations for improving healthcare and education services in rural areas through advanced telecommunications technology, with a focus on addressing substance use disorders and enhancing access to specialized resources.

The "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research" grant aims to encourage existing NCI P50 specialized centers to enhance their current cancer research by integrating new technologies or methods developed by the NCI Innovative Molecular Analysis Technologies program.

This funding opportunity provides financial support for research projects that implement effective treatments for opioid and stimulant use disorders, focusing on improving care systems and addressing health disparities.

This funding opportunity supports states, local governments, and nonprofit organizations in developing community-based programs that help divert individuals with mental health and substance use disorders away from the criminal justice system.

This funding opportunity supports small U.S.-based businesses in developing innovative solutions for population genomic screening to improve primary care practices and enhance patient outcomes.

This funding opportunity is designed for U.S.-based small businesses to develop innovative, cost-effective drug detection devices that can quickly identify both known and new drugs without relying on traditional antibody-based methods.

This grant provides funding for researchers to conduct preclinical studies on the effects of radionuclide-based cancer therapies, aiming to improve treatment strategies and outcomes for cancer patients.

This funding opportunity is designed to establish a center that will coordinate and manage data for collaborative research on rare diseases, supporting various research consortia and engaging stakeholders to improve diagnosis and treatment.

The "Clinical Trial Readiness to Understand and Develop Solutions to Social, Ethical, Behavioral Implications and Barriers to Health Equity in ADRD" grant aims to fund research that prepares for clinical trials focused on understanding and addressing the social, ethical, and behavioral barriers that prevent equal health outcomes for Alzheimer's Disease and Related Dementias (ADRD) in underserved and marginalized communities.

This initiative will support innovative, collaborative, and multi-disciplinary research designed to study the effective adaptation, integration, and implementation of recommended guidelines of care of persons with multiple chronic conditions (MCCs) from populations that experience health disparities. Projects would be expected to involve more than one component and/or more than one level of influence within existing or newly proposed health care models. The ultimate goal of this initiative is attainment of optimal treatment and health outcomes goals in order to move towards health equity.

This grant provides financial support and resources to early-career faculty from underrepresented backgrounds in neuroscience, helping them establish independent research careers through mentorship and protected research time.

This ISO seeks solution summaries and proposals for projects that fall within the general scope of the ARPA-H Scalable Solutions mission office. SSO expands what is technically possible by developing approaches that will leverage an interdisciplinary approach and collaborative networks to address challenges of geography, distribution, manufacturing, data and information, thereby improving health care access and affordability. In the United States, many communities and remote areas lack access to timely and quality health care, which leads to disparities in health outcomes for those populations. Bottlenecks during the manufacturing processes of products and health technologies also lead to delays and limited availability, preventing effective distribution of health care solutions to areas of need, especially in emergencies.ARPA-H SSO seeks solutions to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise by developing location-specific interventions, telemedicine solutions, and mobile health clinics. Solutions should focus on rapid innovation and the use of partnerships, as well as flexible distribution networks and streamlined manufacturing processes. The following SSO interest areas categorize the ground-breaking solutions we seek to support:Scalable Technologies and Interventions: Approaches to improve affordability and equitable access to health care that are adaptable to various geographic, demographic, economic contexts and can be rapidly deployed at scale (e.g., drug-repurposing*, telemedicine, point-of-care diagnostics, and modular health care infrastructure). Tailored solutions for the pediatric population that provide parity in access to treatments and other health care interventions with the adult population and adapt to the pediatric patients changing physiology and developmental status over the course of years. Transformational approaches to reduce or eliminate health disparities, including tools and models for product design and care delivery that scale novel approaches in human factors and human-centered design to respond to full diversity of patients. Tools to enable the scaling of provider and institutional capabilities (e.g., school nurses and schools, walk-in clinics, homesteading care) to address unmet health care access needs and expand availability of critical services. Foundational capabilities to accelerate diagnoses and reduce the cost of treatments for rare diseases wherever patients are, without the need for specialized facilities or healthcare expertise.* Solution summaries and proposals that focus on testing drugs for effectiveness for other disease states or use cases, are unlikely to be funded unless including additional R, or providing gains in cost reduction, accessibility, and/or equity.Collaborative Distribution Networks: Methods for standardization, automation, and democratization of complex procedures 5 including, but not limited to, histopathology, rare disease diagnosis and treatment, and surgical interventions to ensure access and delivery to populations diverse in demographics, geographies, and resources at scale. Approaches to enhance delivery of effective healthcare solutions in rural or low resource settings, including but not limited to "last mile delivery, at-home monitoring, imaging, drug delivery, telehealth augmentation, and support for remote medical procedures with limited need for specialized training. Technologies to enable the deployment of critical healthcare resources rapidly, equitably, and securely at scale to the point of need in permissive and non-permissive (i.e., damaged infrastructure, cyber-denied) environments during a public health crisis or natural disaster. Solutions to scale education and training of critical healthcare resources for health care providers and patients to ensure information integrity to prevent negative impacts to resource use/uptake. Innovative information technology, data and analytic products and technologies to enable ordering, inventory management, situational awareness, allocation planning and demand forecasting of critical healthcare resources during a public health crisis or natural disaster.Biomanufacturing Innovations*: Innovative manufacturing technologies and approaches that reduce cost, shorten the timeline for production, advance domestic competitiveness and reduce supply chain risk of biologics, cellular and gene therapies, pharmaceuticals, medical devices and personal protective equipment. New approaches to support predictable, programable biological production of conventional and novel materials reliability at scale in a cost-effective sustainable manner. Novel solutions to reduce the reliance on specialized handling and cold chain management of pharmaceuticals and biologics. Scalable innovations to advance and strengthen biomanufacturing supply chain and resolve bottlenecks including:o Advances in production of active pharmaceutical ingredients, process consumables, and other critical materials (i.e., enzymes, cell lines, etc);o Novel biomanufacturing-related data products, technologies or models to integrate into supply chain situational awareness systems;o Alternative materials and new manufacturing capabilities for personal protective equipment; ando Improvement of capabilities sustainably re-shore manufacturing and utilize a broad array of readily accessible and cost-efficient feedstocks as part of strengthening the local and national industry base. Analytics and novel sensor systems to precisely manage bioproduction, real-time release assays, and predictive capabilities to inform tuning of biological chassis for efficient and effective scale-up of manufacturing to industrial scale.*ARPA-H is not interested in approaches that merely increase capacity reservation.Other high-quality submissions that propose revolutionary technologies that meet the goals of SSO will be considered even if they do not address the topics listed above.Proposals are expected to use innovative approaches to enable revolutionary advances in medicine and healthcare, and the science and technology underlying these areas. While approaches that are disease agnostic are encouraged, ARPA-H welcomes proposals that bring radically new insights to address specific diseases including, but not limited to, cancer, diabetes, neurological diseases, pediatric and maternal/fetal health, infectious diseases, and cardiovascular disease.Specifically excluded are proposals that represent an evolutionary or incremental advance in the current state of the art or technology that has reached the clinical trial stage. An example of this type of proposal might include the request to fund clinical trials of an otherwise developed product. Additionally, proposals directed towards policy changes, traditional education and training, or center coordination, formation, or development, and construction of physical infrastructure are outside the scope of the ARPA-H mission.

The "Single Source for the Continuation of the Human Pancreas Analysis Program (HPAP) for Type 1 Diabetes (HPAP-T1D)" grant is intended to fund the University of Pennsylvania's ongoing research into understanding and combating Type 1 Diabetes, by studying human pancreatic tissues and immune cells, and sharing their findings through an open-access database.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: (1) Courses for Skills Development; and (2) Develop and implement a program to prepare nurse scientists, and scientists in aligned fields, to conduct research on the social determinants of health in alignment with the NINR Strategic Plan.

The purpose of this NIDCD initiative is to encourage research in the development, characterization, and reproducibility/reliability of human auditory and vestibular organoids.Applications investigating animal organoids are allowable but only if accompanying comparative or other integrated companion studies with human organoids. Singular animal organoid studies alone are not responsive to this funding opportunity. This funding opportunity encourages innovative, reproducible, and novel methodologies and technologies that will drive the reproducibility and holistic longevity of hearing/balance sensory organoids as model systems. The development of novel tools to deliver genes, proteins, molecules, and synthetics that might lead to the successful expansion and longer-term survivability of organoid populations in a stable, reliable, and reproducible manner is highly encouraged. Subsequent characterization of the organoid platforms must be shown to mimic and recapitulate the native correlative biological function. Applications that provide approaches that remove current barriers and lessen challenges to improve current reproducibility and stability are highly encouraged. Applications that have breakthrough approaches and technologies using human auditory/vestibular organoids are highly encouraged.

This funding opportunity supports research aimed at understanding how beliefs about cancer treatment outcomes influence symptom management, particularly focusing on underrepresented populations in biomedical research.

This Funding Opportunity Announcement (FOA) seeks innovative grant applications in nonmalignant hematology research that will steer the field in new directions. Applications to this FOA should propose proof of principle research that is tightly focused into one specific aim, which can be accomplished within a 1-3 year project period, and is directed at validating novel concepts and approaches that promise to open new pathways for discovery.The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute on Aging (NIA) have joined together to build research activities in nonmalignant hematology. This Funding Opportunity Announcement (FOA) is intended to promote innovative research projects in nonmalignant hematology that explore high impact and new directions of inquiry. While each Institute shares interests in nonmalignant hematology research, they also bring different perspectives, thereby expanding the scope of the SHINE II program beyond a single Institute's research mission. This "New Directions in Hematology Research (SHINE-II)" program invites investigator-initiated grant applications for basic or early translational, proof of principle research projects that are tightly focused and directed at validating novel concepts and approaches that promise to advance new pathways for discovery. This program may include clinical research involving human subjects that is directed at understanding disease pathogenesis and prognosis. Research applications submitted under this FOA should be more limited in scope (single aim with sub-aims, as appropriate) and duration (1-3 years) than typical R01 grant applications. The SHINE-II FOA seeks specifically to promote and support new directions of research in their early stages. Applications submitted to this FOA should include preliminary data that support the conceptual basis of the research proposed and the technical approaches to be used. Moreover, while research applications submitted under this FOA are expected to be more limited in scope and shorter in duration than typical R01 applications, achievement of the research objective(s) proposed should validate novel pathways of discovery and provide the basis for future high impact research endeavors. Principal areas of interest for this collaborative FOA include: (1) hematopoietic stem cell biology, (2) lineage fate determinants, (3) aging-related immune dysfunction and lymphocyte biology, (4) myeloid cell biology, and myelopoiesis, (5) platelet biology and dysfunction, (6) erythroid cell biology and erythropoiesis, (7) the molecular biology of heme and hemoglobin, (8) acquired and congenital disorders of red blood cell production and survival leading to chronic anemia or bone marrow failure, (9) and the uptake, utilization, storage, and transport of iron in health and disease. Inquiries to Scientific/Research staff prior to submission of an application to this FOA are strongly encouraged to discuss programmatic relevance and potential time tables for funding (see below, Section VII. Agency Contacts). The limited scope and shorter duration of the SHINE II R01 are not optimal for Early Stage Investigators (ESIs) and New Investigators (NIs), who should contact Scientific/Research staff prior to submission of an application to this FOA.

This funding opportunity provides financial support to state governments and federally recognized Native American tribes for managing the impacts of a deadly bat disease and promoting species conservation efforts.

This grant provides funding to a wide range of organizations, including NGOs and private sector entities, to strengthen local health systems in Guinea, focusing on improving healthcare quality and accessibility in targeted regions.